Pharmanutra
Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 31 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 229,189 kg CO2e, while Scope 2 emissions reached approximately 270,515 kg CO2e (market-based). Notably, Scope 3 emissions were significant, with business travel contributing around 684,328 kg CO2e and employee commute adding about 86,782 kg CO2e. In 2022, the company recorded total emissions of approximately 1,000,000 kg CO2e, with Scope 1 emissions at about 199,150 kg CO2e, Scope 2 at approximately 88,699 kg CO2e, and Scope 3 emissions including purchased goods and services at around 69,491 kg CO2e and waste generated in operations at about 52,821 kg CO2e. Pharmanutra has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. However, the company continues to monitor and report its emissions, indicating a commitment to transparency in its sustainability efforts. As a global player headquartered in Italy, Pharmanutra is positioned to contribute to broader industry efforts in reducing carbon footprints and addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 61,095 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | 000,000.00 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanutra is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
